GO:0120188 regulation of bile acid secretion: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120188 (regulation of bile acid secretion) describes any process that modulates the frequency, rate or extent of the controlled release of bile acid from a cell or tissue.
• Bile acid secretion is tightly controlled by nuclear receptors such as FXR (NR1H4), membrane transporters like BSEP (ABCB11) and MRP2 (ABCC2), and gut microbiota-derived signals.
• Dysregulation of bile acid secretion contributes to cholestatic liver diseases, metabolic disorders, and gastrointestinal cancers.
• Key regulatory inputs include FXR-mediated feedback, FGF19 signaling, and microbial modification of bile acids such as deconjugation and dehydroxylation.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes controlling bile acid secretion.
• Understanding this process is essential for developing therapies targeting bile acid signaling in liver and metabolic diseases.
Description
Bile acids are amphipathic molecules synthesized from cholesterol in hepatocytes and secreted into bile to facilitate lipid digestion and absorption. The process of bile acid secretion is not static; it is dynamically regulated to match metabolic demand and to prevent toxic accumulation of bile acids in the liver and systemic circulation. GO:0120188, regulation of bile acid secretion, captures the biological processes that modulate the frequency, rate or extent of controlled bile acid release from cells or tissues. This regulation is critical because bile acids are also potent signaling molecules that activate nuclear receptors such as FXR and membrane receptors like TGR5, influencing glucose and lipid metabolism, inflammation, and energy homeostasis. Consequently, researchers across hepatology, gastroenterology, endocrinology, and oncology study this process to understand disease mechanisms and identify therapeutic targets. The regulation of bile acid secretion involves a coordinated network of transporters, nuclear receptors, and signaling pathways that sense bile acid levels and adjust secretion accordingly. For example, activation of FXR by bile acids induces expression of FGF19, which feeds back to inhibit bile acid synthesis and secretion. Additionally, gut microbiota modify bile acids, altering their signaling properties and thereby influencing host regulation of secretion. This article provides a comprehensive overview of GO:0120188, covering its definition, molecular mechanisms, key genes, disease relevance, and research methodologies, with a focus on how CRISPR-based models can accelerate discovery.
regulation of bile acid secretion At A Glance
| GO ID | GO:0120188 |
|---|---|
| GO term | regulation of bile acid secretion |
| Ontology | biological_process |
| Synonym | none |
| Major function | Modulates the controlled release of bile acids from cells or tissues |
| Key regulators | FXR (NR1H4), FGF19, BSEP (ABCB11), MRP2 (ABCC2), ASBT (SLC10A2) |
| Associated diseases | Cholestasis, non-alcoholic fatty liver disease, metabolic syndrome, bile acid diarrhea |
| Research methods | CRISPR knockout/knock-in, RNA-seq, ChIP-seq, bile acid profiling, transporter assays |
What Is GO:0120188?
GO:0120188, regulation of bile acid secretion, is defined as any process that modulates the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue. This encompasses signaling events, transporter activity changes, and feedback loops that adjust the amount of bile acids secreted into bile canaliculi or the systemic circulation.
Why Is regulation of bile acid secretion Important in Cell Biology?
Regulation of bile acid secretion is fundamental to maintaining bile acid homeostasis, preventing cholestatic liver injury, and coordinating lipid and glucose metabolism. Because bile acids are both detergents and signaling molecules, their secretion must be precisely tuned; dysregulation leads to pathologies ranging from cholestasis to metabolic syndrome and hepatocellular carcinoma. Understanding the regulatory mechanisms offers opportunities for therapeutic intervention in liver and metabolic diseases.
• Maintains bile acid homeostasis and prevents toxic accumulation in hepatocytes.
• Controls lipid digestion and absorption in the intestine.
• Regulates metabolic signaling through FXR and TGR5, impacting glucose and energy balance.
• Influences gut microbiota composition and function via bile acid modification.
• Dysregulation is linked to cholestatic liver diseases such as primary biliary cholangitis.
• Contributes to the pathogenesis of non-alcoholic fatty liver disease and insulin resistance.
• Plays a role in bile acid diarrhea and irritable bowel syndrome.
• Modulates immune responses and inflammation in the gut and liver.
• Serves as a target for drugs like obeticholic acid (FXR agonist).
• Provides a paradigm for studying nuclear receptor-transporter feedback loops.
What Happens During regulation of bile acid secretion?
Bile acid synthesis and conjugation
In simple terms: The liver makes bile acids from cholesterol and attaches molecules to make them water-soluble.
Bile acid synthesis occurs via classical and alternative pathways, with cholesterol 7alpha-hydroxylase (CYP7A1) as the rate-limiting enzyme. Newly synthesized bile acids are conjugated with taurine or glycine to increase solubility, a step that is also regulated. This synthesis is tightly coupled to secretion because excess bile acids must be exported.
Hepatocyte transport and canalicular secretion
In simple terms: Liver cells pump bile acids out into tiny channels called canaliculi.
The bile salt export pump (BSEP, ABCB11) is the primary transporter mediating ATP-dependent secretion of bile acids into bile canaliculi. MRP2 (ABCC2) exports conjugated bilirubin and other organic anions, and its function is coordinated with BSEP. Regulation of these transporters at transcriptional and post-transcriptional levels determines the rate of bile acid secretion.
FXR-mediated feedback regulation
In simple terms: A sensor called FXR detects bile acids and sends signals to reduce their production and secretion when levels are high.
The farnesoid X receptor (FXR, NR1H4) is activated by bile acids and induces expression of small heterodimer partner (SHP) and FGF19, which inhibit CYP7A1 and bile acid synthesis. FXR also upregulates BSEP and downregulates NTCP (SLC10A1) to reduce bile acid uptake, thereby modulating secretion. This feedback loop is essential for preventing cholestasis.
Gut microbiota and enterohepatic circulation
In simple terms: Gut bacteria change bile acids, and these modified bile acids send signals back to the liver to adjust secretion.
Gut microbiota deconjugate and dehydroxylate bile acids, generating secondary bile acids such as deoxycholic acid and lithocholic acid. These modifications alter FXR signaling; for example, tauro-beta-muricholic acid is an FXR antagonist that is reduced by microbiota, leading to increased FXR activity and altered bile acid secretion. The enterohepatic circulation ensures that bile acids are reabsorbed and returned to the liver, influencing secretion rates.
Hormonal and neural regulation
In simple terms: Hormones and nerves can also tweak how much bile acid is released.
FGF19 (FGF15 in mice) is secreted by the intestine in response to FXR activation and travels to the liver to inhibit CYP7A1 and bile acid secretion. Other hormones such as glucagon and insulin also modulate bile acid metabolism. Neural inputs can affect bile flow, though the mechanisms are less defined.
Key Genes Involved in GO:0120188 regulation of bile acid secretion
The following genes and proteins are central to the regulation of bile acid secretion, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR1H4 (FXR) | Nuclear receptor activated by bile acids; induces FGF19 and SHP to inhibit synthesis and modulate secretion | Target for cholestasis and metabolic disease; knockout models show disrupted bile acid homeostasis |
| ABCB11 (BSEP) | ATP-dependent bile salt export pump; primary transporter for bile acid secretion into canaliculi | Mutations cause progressive familial intrahepatic cholestasis type 2; key for transporter studies |
| ABCC2 (MRP2) | Canalicular transporter for conjugated bilirubin and organic anions; coordinates with BSEP | Defects cause Dubin-Johnson syndrome; relevant for cholestasis research |
| SLC10A1 (NTCP) | Sodium-taurocholate cotransporting polypeptide; mediates hepatic uptake of bile acids | FXR downregulates NTCP to reduce bile acid load; target for hepatitis B entry studies |
| SLC10A2 (ASBT) | Apical sodium-dependent bile acid transporter in ileum; mediates reabsorption | Inhibition increases fecal bile acid loss; studied for bile acid diarrhea |
| CYP7A1 | Rate-limiting enzyme in classical bile acid synthesis pathway | Feedback regulated by FXR-FGF19; knockout models show altered bile acid pool |
| CYP8B1 | Sterol 12alpha-hydroxylase; determines cholic acid synthesis | Regulates bile acid composition; relevant for gallstone disease |
| FGF19 | Intestinal hormone induced by FXR; inhibits CYP7A1 and bile acid synthesis | Therapeutic target for cholestasis and metabolic disorders |
| SHP (NR0B2) | Orphan nuclear receptor; mediates FXR inhibition of CYP7A1 | Knockout models show impaired feedback regulation |
| TGR5 (GPBAR1) | Membrane bile acid receptor; mediates metabolic and anti-inflammatory effects | Target for metabolic and inflammatory diseases |
| VDR | Vitamin D receptor; activated by secondary bile acids like LCA | Modulates bile acid detoxification and secretion |
| PXR (NR1I2) | Pregnane X receptor; induces CYP3A4 and OATP2 to detoxify bile acids | Xenobiotic receptor that cross-talks with bile acid regulation |
| OSTalpha/OSTbeta | Organic solute transporters; mediate basolateral efflux of bile acids | Alternative secretion route; upregulated in cholestasis |
| MRP3 (ABCC3) | Basolateral efflux transporter for bile acids | Compensatory pathway in cholestasis; studied in knockout models |
| MRP4 (ABCC4) | Basolateral efflux transporter for bile acids and sulfated steroids | Upregulated in liver injury; potential target |
| AKR1D1 | Delta4-3-oxosteroid 5beta-reductase; required for bile acid synthesis | Deficiency causes neonatal cholestasis; relevant for rare disease |
| CYP27A1 | Sterol 27-hydroxylase; alternative pathway for bile acid synthesis | Mutations cause cerebrotendinous xanthomatosis |
| SLC51A/B | Organic solute transporter subunits; mediate bile acid efflux from enterocytes | Essential for enterohepatic circulation; knockout models show bile acid malabsorption |
How Is regulation of bile acid secretion Regulated?
Regulation of bile acid secretion is primarily controlled by the nuclear receptor FXR, which senses bile acid levels and induces FGF19 and SHP to inhibit CYP7A1 and modulate transporters. Gut microbiota influence this regulation by modifying bile acids; for instance, reduction of tauro-beta-muricholic acid by microbiota enhances FXR signaling. Additionally, circadian rhythms and feeding status affect bile acid secretion through clock genes and hormonal signals. Post-translational modifications of transporters, such as phosphorylation, can also acutely regulate their activity.
regulation of bile acid secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB11 | Progressive familial intrahepatic cholestasis type 2 | Knockout mice or patient-derived organoids with point mutations |
| NR1H4 | Primary biliary cholangitis, metabolic syndrome | Liver-specific FXR knockout mice; FXR agonist treatment |
| FGF19 | Cholestasis, metabolic disorders | Transgenic overexpression or knockout models |
| SLC10A2 | Bile acid diarrhea | ASBT knockout mice or intestinal organoids |
| CYP7A1 | Gallstone disease, hypercholesterolemia | Knockout or humanized mouse models |
Cholestatic liver diseases
Impaired regulation of bile acid secretion leads to cholestasis, characterized by bile acid accumulation and liver injury. Mutations in ABCB11 (BSEP) cause progressive familial intrahepatic cholestasis, and FXR dysfunction contributes to primary biliary cholangitis. Therapies like obeticholic acid target FXR to restore regulation.
Metabolic disorders
Dysregulated bile acid secretion is linked to non-alcoholic fatty liver disease, insulin resistance, and obesity. FXR and TGR5 signaling influence glucose and lipid metabolism, making regulation of bile acid secretion a therapeutic target for metabolic syndrome.
Gastrointestinal cancers
Chronic exposure to secondary bile acids due to altered secretion and microbiota increases risk of colorectal and hepatocellular cancers. FXR activation has protective effects, and its dysregulation is implicated in tumorigenesis.
Bile acid diarrhea
Excessive bile acid secretion or impaired reabsorption can cause bile acid diarrhea, a common condition in irritable bowel syndrome. ASBT inhibitors are used to manage this by reducing bile acid reabsorption.
From regulation of bile acid secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FXR alter bile acid secretion? | Liver-specific FXR knockout mouse |
| How do point mutations in ABCB11 affect BSEP function? | CRISPR point-mutation knock-in in HepG2 or organoids |
| Can overexpression of FGF19 reduce bile acid synthesis? | Adeno-associated virus-mediated overexpression in mice |
| What is the role of gut microbiota in regulating secretion? | Germ-free or antibiotic-treated mice with fecal transplant |
| Does ASBT inhibition affect bile acid diarrhea? | ASBT knockout mice or intestinal organoids |
| How does circadian rhythm influence bile acid secretion? | Clock gene knockout mice with bile acid profiling |
How to Study the regulation of bile acid secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS bile acid profiling | Concentrations of individual bile acid species | Assessing secretion in knockout mice or patient samples |
| RNA-seq | Transcriptome changes | Identifying FXR target genes in liver or intestine |
| ChIP-seq | FXR binding sites | Mapping direct regulatory elements of bile acid genes |
| Transport assays | Transporter activity | Measuring BSEP or ASBT function in vitro |
| CRISPR knockout screens | Genes required for bile acid secretion | Discovery of novel regulators |
| Organoid culture | Bile acid secretion in 3D | Patient-derived models for cholestasis |
| Microbiota sequencing | Gut microbial composition | Linking microbiota to bile acid modification |
| In vivo bile collection | Bile flow and composition | Evaluating secretion rate in animal models |
Bile acid profiling
Quantification of bile acids in serum, bile, feces, and urine using LC-MS/MS or GC-MS is essential to assess secretion rates and pool composition. This method reveals changes in primary and secondary bile acids and can be applied to knockout or treatment models.
Transcriptomics and ChIP-seq
RNA-seq identifies changes in gene expression of transporters and enzymes, while ChIP-seq for FXR reveals direct target genes involved in regulation of bile acid secretion. These methods are powerful when combined with CRISPR knockout of candidate regulators.
Transport assays
In vitro transport assays using polarized cell lines (e.g., HepG2, Caco-2) or membrane vesicles measure BSEP, MRP2, or ASBT activity. Fluorescent bile acid analogs enable live-cell imaging of secretion.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify novel regulators of bile acid secretion. For example, a screen for modifiers of BSEP trafficking or FXR activity could uncover new therapeutic targets.
How CRISPR Can Be Used to Study GO:0120188 regulation of bile acid secretion
Knockout
CRISPR knockout of genes such as NR1H4 (FXR), ABCB11 (BSEP), or SLC10A2 (ASBT) in cell lines or mice enables causal testing of their role in regulation of bile acid secretion. For example, FXR knockout mice exhibit altered bile acid pool and impaired feedback regulation.
Point Mutation
Introducing disease-associated point mutations (e.g., in ABCB11) via CRISPR base editing or HDR allows study of transporter dysfunction and its impact on bile acid secretion, mimicking human cholestasis.
Knock-in
Knock-in of reporter tags (e.g., GFP) or humanized alleles (e.g., human FXR) facilitates live imaging of transporter localization and species-specific regulation of bile acid secretion.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of FGF19 or constitutively active FXR can enhance repression of bile acid synthesis and reduce secretion, providing models for therapeutic intervention.
How EDITGENE Supports regulation of bile acid secretion Research
Researchers studying regulation of bile acid secretion-related genes often need to determine whether a candidate gene is causally involved in controlling bile acid release, and CRISPR-based models provide the most direct approach for such functional validation.
Contact EDITGENE today to design your custom CRISPR model for regulation of bile acid secretion research.
Frequently Asked Questions About regulation of bile acid secretion
What is GO:0120188?
GO:0120188 is the Gene Ontology term for regulation of bile acid secretion, defined as any process that modulates the frequency, rate or extent of the controlled release of bile acid from a cell or a tissue.
What genes are involved in regulation of bile acid secretion?
Key genes include NR1H4 (FXR), ABCB11 (BSEP), ABCC2 (MRP2), SLC10A1 (NTCP), SLC10A2 (ASBT), CYP7A1, FGF19, and SHP (NR0B2).
How is bile acid secretion regulated?
It is regulated by nuclear receptor FXR, which senses bile acids and induces FGF19 and SHP to inhibit synthesis and modulate transporters; gut microbiota also play a role by modifying bile acids.
What diseases are associated with dysregulated bile acid secretion?
Cholestatic liver diseases, metabolic syndrome, bile acid diarrhea, and gastrointestinal cancers are linked to dysregulation of bile acid secretion.
What methods are used to study regulation of bile acid secretion?
Common methods include bile acid profiling by LC-MS/MS, RNA-seq, ChIP-seq, transport assays, and CRISPR screens.
How can CRISPR be used to study bile acid secretion?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes like FXR and BSEP in bile acid secretion.
What is the role of FXR in bile acid secretion?
FXR is a nuclear receptor activated by bile acids that induces FGF19 and SHP, leading to inhibition of CYP7A1 and modulation of BSEP and NTCP to control secretion.
How does gut microbiota affect bile acid secretion?
Microbiota deconjugate and dehydroxylate bile acids, altering FXR signaling; for example, reduction of tauro-beta-muricholic acid enhances FXR activity and changes secretion.
What are the therapeutic targets for bile acid secretion disorders?
FXR agonists (e.g., obeticholic acid), FGF19 analogs, and ASBT inhibitors are being developed for cholestasis, metabolic diseases, and bile acid diarrhea.
Why is regulation of bile acid secretion important?
It maintains bile acid homeostasis, prevents liver toxicity, and coordinates lipid and glucose metabolism, making it critical for health and disease.
Conclusion
Regulation of bile acid secretion (GO:0120188) is a vital biological process that integrates nuclear receptor signaling, transporter activity, and gut microbiota to maintain bile acid homeostasis. Dysregulation contributes to a range of diseases, from cholestasis to metabolic syndrome, making it a rich area for therapeutic targeting. CRISPR-based models offer powerful tools to dissect the causal roles of specific genes and to identify novel regulators. EDITGENE provides comprehensive services to support such research, from knockout and knock-in models to library screening and bioinformatics.
References
- 1. Jia W et al.. 2024. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis.. Sci China Life Sci 67(5):865-878 PMID: 37515688
- 2. Ramírez-Pérez O et al.. 2017. The Role of the Gut Microbiota in Bile Acid Metabolism.. Ann Hepatol 16(Suppl. 1: s3-105.):s15-s20 PMID: 29080339
- 3. Chiang JY. 2013. Bile acid metabolism and signaling.. Compr Physiol 3(3):1191-212 PMID: 23897684
- 4. Cai J et al.. 2022. Bile acid metabolism and signaling, the microbiota, and metabolic disease.. Pharmacol Ther 237:108238 PMID: 35792223
- 5. Chiang JYL et al.. 2022. Discovery of farnesoid X receptor and its role in bile acid metabolism.. Mol Cell Endocrinol 548:111618 PMID: 35283218
- 6. Di Ciaula A et al.. 2017. Bile Acid Physiology.. Ann Hepatol 16(Suppl. 1: s3-105.):s4-s14 PMID: 29080336
- 7. Sayin SI et al.. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.. Cell Metab 17(2):225-35 PMID: 23395169
- 8. Boyer JL. 2013. Bile formation and secretion.. Compr Physiol 3(3):1035-78 PMID: 23897680
